Aldeyra Therapeutics, Inc to Post Q2 2018 Earnings of ($0.39) Per Share, Seaport Global Securities Forecasts (ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Stock analysts at Seaport Global Securities issued their Q2 2018 EPS estimates for Aldeyra Therapeutics in a note issued to investors on Wednesday, May 16th. Seaport Global Securities analyst C. Davis forecasts that the biotechnology company will earn ($0.39) per share for the quarter. Seaport Global Securities has a “Buy” rating on the stock.

Several other brokerages also recently weighed in on ALDX. Canaccord Genuity restated a “buy” rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Cantor Fitzgerald set a $23.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Tuesday. ValuEngine upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. Finally, Cowen restated a “hold” rating on shares of Aldeyra Therapeutics in a research note on Monday, April 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $16.93.

Shares of Aldeyra Therapeutics opened at $9.17 on Friday, Marketbeat Ratings reports. The firm has a market capitalization of $178.97 million, a PE ratio of -6.55 and a beta of 0.55. The company has a quick ratio of 13.12, a current ratio of 11.09 and a debt-to-equity ratio of 0.03. Aldeyra Therapeutics has a twelve month low of $8.35 and a twelve month high of $8.50.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Tuesday, May 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06).

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in Aldeyra Therapeutics by 19.8% in the first quarter. JPMorgan Chase & Co. now owns 59,502 shares of the biotechnology company’s stock valued at $446,000 after acquiring an additional 9,826 shares in the last quarter. Woodstock Corp raised its holdings in Aldeyra Therapeutics by 20.4% in the fourth quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 9,850 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Aldeyra Therapeutics by 22.6% in the first quarter. Dimensional Fund Advisors LP now owns 62,429 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 11,506 shares in the last quarter. Northern Trust Corp raised its holdings in Aldeyra Therapeutics by 34.3% in the first quarter. Northern Trust Corp now owns 48,151 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 12,290 shares in the last quarter. Finally, Element Capital Management LLC acquired a new stake in Aldeyra Therapeutics in the first quarter valued at $123,000. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Set Clipper Realty  Price Target at $14.63
Brokerages Set Clipper Realty Price Target at $14.63
Zacks: Brokerages Anticipate Amyris Inc  Will Post Quarterly Sales of $37.53 Million
Zacks: Brokerages Anticipate Amyris Inc Will Post Quarterly Sales of $37.53 Million
Brokerages Set Ameresco Inc  PT at $13.17
Brokerages Set Ameresco Inc PT at $13.17
Brokerages Set Gaia, Inc.  Target Price at $21.50
Brokerages Set Gaia, Inc. Target Price at $21.50
Brokerages Anticipate Chesapeake Energy Co.  Will Announce Earnings of $0.13 Per Share
Brokerages Anticipate Chesapeake Energy Co. Will Announce Earnings of $0.13 Per Share
Safe Exchange Coin  Trading Up 6.8% Over Last 7 Days
Safe Exchange Coin Trading Up 6.8% Over Last 7 Days


Leave a Reply

© 2006-2018 Ticker Report. Google+.